An Open Label Extension Study in Participants With Rheumatoid Arthritis

Inclusion Criteria:

- Have given written informed consent

- Women must not be pregnant, breastfeeding or be at risk to become pregnant during
study participation

- Have participated in either Study H9B-MC-BCDG (NCT00689728) or Study H9B-MC-BCDH
(NCT00785928)

Exclusion Criteria:

- Have had, during Study H9B-MC-BCDG (NCT00689728) or Study H9B-MC-BCDH (NCT00785928),
any safety event, [including having a recent, ongoing, or serious infection, a serious
drug reaction, or any adverse event (AE) that caused discontinuation from treatment]
that in the opinion of the investigator poses an unacceptable risk to participation in
the study.

- Have received, during Study H9B-MC-BCDG (NCT00689728) or Study H9B-MC-BCDH
(NCT00785928), any drug not allowed by the study protocol including unapproved drugs,
biologic disease-modifying anti-rheumatic drugs (DMARDs), or live vaccines.

- Enrollment in any other clinical trial involving off-label use of an investigational
drug or device, or enrollment in any other type of medical research.